Mark Peterson

By partnering with manufacturing giant Sanmina, Microbot Medical is telegraphing its shift from a promising MedTech firm to a serious global contender.

As Richelieu Hardware preps its Q2 results, all eyes are on whether its growth strategy can defy North America's economic headwinds. A critical test.

A new investigation reveals the core strategy behind outlet malls: a two-tiered market where brands sell lower-quality goods, not genuine bargains.

Beyond the baseball diamond in Fuzhou lies a strategic play. China is leveraging a century-old bond to court 50,000 young Americans, a long-term investment in shaping future ties.

With FDA Priority Review for its at-home therapy Enspryng, Roche is signaling a major disruption in the lucrative Thyroid Eye Disease market.

Firms are realizing that agile speed without strategic direction is chaos. A new blueprint from Info-Tech Research Group argues for a radical restructure.

A new 'radical collaboration' between top cancer centers is leveraging recent drug breakthroughs to develop combination therapies for pancreatic cancer's deadliest mutation.

A $43M order for Gilat's Sidewinder antenna isn't just a sale; it's a major signal of the industry's shift to multi-orbit networks for superior Wi-Fi in the sky.

Hilton's inaugural ownership award to Canada's Gupta Group is more than a trophy; it's a strategic signal about the future of hospitality investment.

How one Indian chemical plant's elite WEF recognition offers a blueprint for combining AI-driven productivity with deep sustainability gains.

As pharma giants battle over injectable weight-loss drugs, a biotech firm is making a strategic play to awaken the body's own metabolic machinery. Is this the future?

At Intersolar Europe, Kehua Digital Energy didn't just launch products; it unveiled a blueprint for grid stability in a renewable-heavy world. This is the story of why that matters.

CIEE's tour celebrates the BridgeUSA program's economic boost to places like Mackinac Island. But a closer look reveals a complex debate over its true purpose.

The high court's 7-2 decision on Roundup not only ends a legal saga for Bayer but signals a major shift in product liability across all federally regulated industries.

A new gaming studio is betting that AI doppelgangers of celebrities playing poker can redefine spectator sports. Can blockchain tech ensure a fair game?

An award for Quantori's ML-driven molecular design tool highlights a crucial shift in pharma R&D: moving from AI hype to practical, real-world execution.

N-able partners with Trigent to launch a key India R&D hub, signaling a strategic shift to harness local AI talent for next-gen global cyber defense.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

As AI moves from generating answers to executing commands, a new partnership aims to build the essential guardrails for this autonomous corporate frontier.

The specialist manufacturer's oversubscribed IPO signals more than market confidence; it's a strategic move to dominate the future of aerospace and energy.